We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Johnson & Johnson announced Wednesday that an FDA advisory panel voted against recommending approval of its experimental rheumatoid arthritis (RA) therapy Plivensia (sirukumab). Citing safety concerns, the panel voted 12 to 1 that the benefits of the drug